Therapeutics of Wegener's granulomatosis (Q36577459)

15 August 2017

1 reference

title

Therapeutics of Wegener's granulomatosis (English)

1 reference

15 August 2017

Peter K Wung

1

1 reference

PubMed ID

16932685

15 August 2017

John H Stone

series ordinal

2

1 reference

15 August 2017

1 April 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

4

1 reference

15 August 2017

192-200

1 reference

Wegener Granulomatosis: An Analysis of 158 Patients

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

Comparison of mesna with forced diuresis to prevent cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

The Use of Alkylating Agents in the Treatment of Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Effect of Cyclophosphamide upon the Immune Response in Wegener's Granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Design of the Wegener's Granulomatosis Etanercept Trial (WGET).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener’s granulomatosis: extended follow-up and rate of relapse

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Pneumocystis carinii pneumonia in patients without HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Pneumocystis carinii Pneumonia as a Complication of Immunosuppressive Therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Atovaquone Compared with Dapsone for the Prevention ofPneumocystis cariniiPneumonia in Patients with HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Urinary bladder cancer in Wegener's granulomatosis: is it more than cyclophosphamide?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Fracture risk associated with systemic and topical corticosteroids

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Intravenous immunoglobulin as sole therapy for systemic vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Immunosuppression in ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Maintenance of remission with leflunomide in Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

The immunosuppressant 15-deoxyspergualin [correction of 1,5-deoxyspergualin] reveals commonality between preT and preB cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0139

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0139

1 reference

release_irkdmagmqranvdxqbuuflc3dlu

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/irkdmagmqranvdxqbuuflc3dlu

24 November 2022

mapped directly with Wikidata item

PubMed ID

16932685

1 reference

PubMed ID

16932685